Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa

Many antimalarials sold in sub-Saharan Africa are poor-quality (falsified, substandard, or degraded), and the burden of disease caused by this problem is inadequately quantified. In this article, we estimate the number of under-five deaths caused by ineffective treatment of malaria associated with consumption of poor-quality antimalarials in 39 sub-Saharan countries. Using Latin hypercube sampling our estimates were calculated as the product of the number of private sector antimalarials consumed by malaria-positive children in 2013; the proportion of private sector antimalarials consumed that were of poor-quality; and the case fatality rate (CFR) of under-five malaria-positive children who did not receive appropriate treatment. An estimated 122,350 (interquartile range [IQR]: 91,577–154,736) under-five malaria deaths were associated with consumption of poor-quality antimalarials, representing 3.75% (IQR: 2.81–4.75%) of all under-five deaths in our sample of 39 countries. There is considerable uncertainty surrounding our results because of gaps in data on case fatality rates and prevalence of poor-quality antimalarials. Our analysis highlights the need for further investigation into the distribution of poor-quality antimalarials and the need for stronger surveillance and regulatory efforts to prevent the sale of poor-quality antimalarials.

[1]  Patricia Tabernero,et al.  Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database , 2014, Malaria Journal.

[2]  M. Gharbi,et al.  Trends in Antimalarial Drug Use in Africa , 2013, The American journal of tropical medicine and hygiene.

[3]  L. Gostin,et al.  Countering the Problem of Falsified and Substandard Drugs , 2013 .

[4]  Justin M. Cohen,et al.  Optimizing Investments in Malaria Treatment and Diagnosis , 2012, Science.

[5]  Paul N Newton,et al.  Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. , 2012, The Lancet. Infectious diseases.

[6]  P. Newton,et al.  The WWARN Antimalarial Quality Surveyor , 2012, Pathogens and global health.

[7]  Alan D. Lopez,et al.  Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.

[8]  Arantxa Roca-Feltrer,et al.  Estimating the potential public health impact of seasonal malaria chemoprevention in African children , 2012, Nature Communications.

[9]  P. Newton,et al.  Poor quality vital anti-malarials in Africa - an urgent neglected public health priority , 2011, Malaria Journal.

[10]  P. Newton,et al.  The Primacy of Public Health Considerations in Defining Poor Quality Medicines , 2011, PLoS Medicine.

[11]  C. Goodman,et al.  Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries , 2011, Malaria Journal.

[12]  C. Goodman,et al.  The ACTwatch project: methods to describe anti-malarial markets in seven countries , 2011, Malaria Journal.

[13]  Anne Mills,et al.  Likely Health Outcomes for Untreated Acute Febrile Illness in the Tropics in Decision and Economic Models; A Delphi Survey , 2011, PloS one.

[14]  N. Siva Tackling the booming trade in counterfeit drugs , 2010, The Lancet.

[15]  David L. Smith,et al.  Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty , 2010, Malaria Journal.

[16]  P. Newton,et al.  Impact of poor-quality medicines in the ‘developing’ world , 2010, Trends in pharmacological sciences.

[17]  David A. Fidock,et al.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.

[18]  R. Maude,et al.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance , 2009, Malaria Journal.

[19]  P. Newton,et al.  Guidelines for Field Surveys of the Quality of Medicines: A Proposal , 2009, PLoS medicine.

[20]  N. White,et al.  Qinghaosu (Artemisinin): The Price of Success , 2008, Science.

[21]  P. Newton,et al.  Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. , 2008, The American journal of tropical medicine and hygiene.

[22]  I. Okeke,et al.  Antimicrobial resistance in developing countries , 1998, BMJ.

[23]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[24]  R. Cibulskis,et al.  World Malaria Report 2013 , 2014 .

[25]  P. Newton,et al.  Counterfeit and Substandard Anti-infectives in Developing Countries , 2010 .

[26]  Weltgesundheitsorganisation World malaria report , 2005 .